Clinical Trial Update: Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ibrutinib in previously untreated Binet stage A chronic lymphocytic leukemia at risk of progression has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: German CLL Study Group | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: COMPLETED